GAD1

GAD1 Liste de produits

Attribut
Protein (1)
Bibliothèque de produits
En ligne (1)
Espèces
Human (1)
Étiquette
His Tag (1)
Marqueur
Unconjugated (1)

Numéro de produit	Espèces	Système d'expression	Description du produit	Structure protéique	Pureté	Caractéristiques	Pré-commande/Commande
GA1-H5543	Human	InsectCells	Human GAD1 / GAD67 Protein, His Tag				Ajouter au panier

Quantité totale1

GAD1Contexte de la molécule

Glutamate decarboxylase or glutamic acid decarboxylase (GAD) is an enzyme that catalyzes the decarboxylation of glutamate to gamma-aminobutyric acid (GABA), the major inhibitory transmitter in higher brain regions, and putative paracrine hormone in pancreatic islets. GAD uses pyridoxal-phosphate (PLP) as a cofactor.Two molecular forms of GAD (65 kDa and 67 kDa) are highly conserved and both are expressed in the CNS, pancreatic islet cells, testis, oviduct and ovary. The isoforms are regionally distributed cytoplasmically in the brains of rats and mice. GAD65 is an ampiphilic, membrane-anchored protein (585 a.a.), and is responsible for vesicular GABA production. GAD67 is cytoplasmic (594 a.a.), and seems to be responsible for significant cytoplasmic GABA production.

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Dapirolizumab pegol	Anti-CD40L-Fab; Anti-CD40L-Fab-PEG; CDP-7657; CD40L - Fab; BIIB-133	Phase 3 Clinical	Biogen Inc, Ucb	Autoimmune Diseases; Connective Tissue Diseases; Immune System Diseases; Lupus Erythematosus, Systemic; Skin and Connective Tissue Diseases	Details
Dazodalibep	VIB-4920; MEDI-4920; HZN-4920(Horizon Therapeutics); UNII-HN5US76BWF; WHO-11399	Phase 3 Clinical	Medimmune Llc, Horizon Therapeutics PLC	Rejection of renal transplantation; Sjogren's Syndrome; Arthritis, Rheumatoid; Lupus Nephritis; Rejection of organ transplantation; Sjogren-Larsson Syndrome	Details
Frexalimab	INX-021; SAR-441344	Phase 3 Clinical	Immunext Inc	Diabetes Mellitus, Type 1; Sjogren's Syndrome; Multiple Sclerosis; Lupus Erythematosus, Systemic; Glomerulosclerosis, Focal Segmental; Sjogren-Larsson Syndrome; Glomerulonephritis	Details
Anti-CD40L antibody (Bristol-Myers Squibb)		Phase 2 Clinical	Bristol-Myers Squibb Company	Immunologic Deficiency Syndromes	Details
AdCD40L		Phase 2 Clinical	Uppsala University	Urinary Bladder Neoplasms; Melanoma	Details
Tegoprubart	AT-1501	Phase 2 Clinical	Als Therapy Development Institute	Diabetes Mellitus, Type 1; Rejection of renal transplantation; Glomerulonephritis, IGA; Diabetes Mellitus; Amyotrophic Lateral Sclerosis	Details
Delolimogene mupadenorepvec	LOAd-703	Phase 2 Clinical	Uppsala University, Lokon Pharma	Biliary Tract Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Melanoma	Details
CD40 ligand expressing MSLN-CAR T cells		Phase 2 Clinical	Pla General Hospital	Solid tumours	Details
CD40L-augmented Tumor Infiltrating Lymphocytes (H Lee Moffitt Cancer Center & Research Institute)		Phase 2 Clinical	H Lee Moffitt Cancer Center & Research Institute	Carcinoma, Non-Small-Cell Lung	Details
Letolizumab	BMS-986004; BMS2h-572-633-CT-L2	Phase 1 Clinical	Bristol-Myers Squibb Company	Purpura, Thrombocytopenic, Idiopathic; Graft vs Host Disease	Details
TNX-1500	TNX-1500	Phase 1 Clinical	Tonix Pharmaceuticals Holding Corp	Autoimmune Diseases; Rejection of organ transplantation; Autoimmune Diseases of the Nervous System	Details
MEM-288	MEM-288	Phase 1 Clinical	Memgen	Solid tumours; Head and Neck Neoplasms; Carcinoma, Merkel Cell; Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma	Details
IBI355	IBI-355	Phase 1 Clinical	Innovent Biologics(Suzhou) Co Ltd	Sjogren's Syndrome; Lupus Erythematosus, Systemic	Details
APB-A1	APB-A1; Lu-AG22515	Phase 1 Clinical	AprilBio Co Ltd	Graves Ophthalmopathy; Neuromyelitis Optica	Details